Adaptive Biotechnologies Corporation $ADPT Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC increased its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 52.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 214,605 shares of the company’s stock after purchasing an additional 73,716 shares during the period. Calamos Advisors LLC owned 0.14% of Adaptive Biotechnologies worth $2,500,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. lifted its stake in Adaptive Biotechnologies by 801.6% in the first quarter. Ameriprise Financial Inc. now owns 6,642,476 shares of the company’s stock valued at $49,355,000 after buying an additional 5,905,756 shares during the last quarter. Braidwell LP acquired a new stake in shares of Adaptive Biotechnologies in the 1st quarter worth about $35,692,000. Iron Triangle Partners LP acquired a new stake in shares of Adaptive Biotechnologies in the 1st quarter worth about $15,856,000. Victory Capital Management Inc. boosted its stake in Adaptive Biotechnologies by 9,892.2% during the 1st quarter. Victory Capital Management Inc. now owns 1,764,227 shares of the company’s stock valued at $13,108,000 after purchasing an additional 1,746,571 shares during the period. Finally, Driehaus Capital Management LLC boosted its stake in Adaptive Biotechnologies by 154.4% during the 1st quarter. Driehaus Capital Management LLC now owns 2,152,335 shares of the company’s stock valued at $15,992,000 after purchasing an additional 1,306,164 shares during the period. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Price Performance

ADPT opened at $14.14 on Friday. The business has a 50 day moving average price of $14.98 and a two-hundred day moving average price of $12.24. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -17.24 and a beta of 2.09. Adaptive Biotechnologies Corporation has a 1-year low of $4.27 and a 1-year high of $17.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 60.93% and a negative net margin of 59.07%.The company had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. During the same quarter in the previous year, the business earned ($0.22) EPS. The company’s quarterly revenue was up 102.4% compared to the same quarter last year. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ADPT shares. TD Cowen raised their price target on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Piper Sandler increased their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. Guggenheim began coverage on Adaptive Biotechnologies in a research note on Tuesday, September 30th. They set a “buy” rating and a $20.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Finally, BTIG Research increased their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.56.

Insider Activity

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 10,000 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $14.82, for a total value of $148,200.00. Following the completion of the sale, the insider directly owned 1,269,524 shares of the company’s stock, valued at approximately $18,814,345.68. This represents a 0.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Chad M. Robins sold 1,867 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $15.00, for a total transaction of $28,005.00. Following the transaction, the chief executive officer owned 2,869,975 shares of the company’s stock, valued at approximately $43,049,625. This trade represents a 0.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 99,265 shares of company stock worth $1,463,380. 6.40% of the stock is owned by company insiders.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.